A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Healthy Volunteers
- healthy people welcome
- Location
- at UCSD UCSF
- Dates
- study startedstudy ends around
- Principal Investigator
- by Mark Walters (ucsf)
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at University of California Health
- Mark Walters (ucsf)
The over-arching goal of my research career has been to develop and expand curative therapies for hemoglobin disorders in particular and non-malignant hematopoietic disorders more broadly. I have focused on genome editing approaches most recently, which rely upon modification of autologous hematopoietic cells to elicit a curative effect.
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Bristol-Myers Squibb
- ID
- NCT06481306
- Phase
- Phase 1/2 research study
- Study Type
- Interventional
- Participants
- Expecting 224 study participants
- Last Updated